Literature DB >> 11378657

Development of new heparin-like compounds and other antithrombotic drugs and their interaction with vascular endothelial cells.

H B Nader1, M A Pinhal, E C Baú, R A Castro, G F Medeiros, S F Chavante, E L Leite, E S Trindade, S K Shinjo, H A Rocha, I L Tersariol, A Mendes, C P Dietrich.   

Abstract

The anticlotting and antithrombotic activities of heparin, heparan sulfate, low molecular weight heparins, heparin and heparin-like compounds from various sources used in clinical practice or under development are briefly reviewed. Heparin isolated from shrimp mimics the pharmacological activities of low molecular weight heparins. A heparan sulfate from Artemia franciscana and a dermatan sulfate from tuna fish show a potent heparin cofactor II activity. A heparan sulfate derived from bovine pancreas has a potent antithrombotic activity in an arterial and venous thrombosis model with a negligible activity upon the serine proteases of the coagulation cascade. It is suggested that the antithrombotic activity of heparin and other antithrombotic agents is due at least in part to their action on endothelial cells stimulating the synthesis of an antithrombotic heparan sulfate.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11378657     DOI: 10.1590/s0100-879x2001000600002

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  2 in total

1.  Crude Heparin Preparations Unveil the Presence of Structurally Diverse Oversulfated Contaminants.

Authors:  Aline Mendes; Maria C Z Meneghetti; Marcelly Valle Palladino; Giselle Zenker Justo; Guilherme L Sassaki; Jawed Fareed; Marcelo A Lima; Helena B Nader
Journal:  Molecules       Date:  2019-08-17       Impact factor: 4.411

2.  Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo.

Authors:  P Mellor; J R Harvey; K J Murphy; D Pye; G O'Boyle; T W J Lennard; J A Kirby; S Ali
Journal:  Br J Cancer       Date:  2007-08-28       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.